Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in District of Columbia: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with kidney cancer that has spr…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04510597
Sites in District of Columbia: - MedStar Washington Hospital Center — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting NIH
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in District of Columbia: - Children's National Hospital (Data Collection Only) — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07293351
Sites in District of Columbia: - Local Institution - 0134 — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The pr…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05135975
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06376669
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in District of Columbia: - John Hopkins Kimmer Cancer Center — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in particip…
Sponsor: Children's National Research Institute
NCT ID: NCT07172958
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
- Childrens National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Recruiting NIH
Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have c…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01109394
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia